In his weekly clinical update, Dr. Griffin with Vincent Racaniello discusses outbreaks of Vibrio vulnificus and Legionnaire’s disease in Harlem, the role of the American Association of Pediatrics defining immunization practices, before Dr. Griffin deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, effective of the high and low does influenza vaccines, association Gullian-Barre syndrome with RSV vaccination, guidelines for using RSV vaccines, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines, where to find PEMGARDA, long COVID treatment center, where to go for answers to your long COVID questions, vascular aging after COVID-19 and contacting your federal government representative to stop the assault on science and biomedical research.
Click arrow to play
Download TWiV 1246 (32 MB .mp3, 54 min)
Subscribe (free): Apple Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Department of Public Health alerts public to rare Vibrio vulnificus bacteria in coastal waters (Mass.gov)
- Legionnaires’ Disease: In Harlem (NYC Health)
- Ivermectin to Control Malaria (NEJM)
- AAP has been leading voice on childhood vaccine recommendations since 1930s
- (American Academy of Pediatrics)
- The American Academy of Pediatrics Releases Its Own Evidence-Based Immunization Schedule (American Academy of Pediatrics)
- Wastewater for measles (WasterWater Scan)
- Measles cases and outbreaks (CDC Rubeola)
- Weekly measles and rubella monitoring (Government of Canada)
- Health Ministry says unvaccinated 18-month-old dies of measles (Times of Israel)
- Ten countries in the Americas report measles outbreaks in 2025 (PAHO: Pan American Health Organization)
- Measles (WHO)
- Get the FACTS about measles (NY State Department of Health)
- Measles vaccine recommendations from NYP (jpg)
- Measles (CDC Measles (Rubeola))
- Measles vaccine (CDC Measles (Rubeola))
- Presumptive evidence of measles immunity (CDC)
- Contraindications and precautions to measles vaccination (CDC)
- Measles (CDC Measles (Rubeola))
- Adverse events associated with childhood vaccines: evidence bearing on causality (NLM)
- Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America)
- Deaths following vaccination: what does the evidence show (Vaccine)
- Influenza: Waste water scan for 11 pathogens (WastewaterSCan)
- US respiratory virus activity (CDC Respiratory Illnesses)
- Respiratory virus activity levels (CDC Respiratory Illnesses)
- Weekly surveillance report: clift notes (CDC FluView)
- Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score (JID)
- FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA)
- RSV: Waste water scan for 11 pathogens (WastewaterSCan)
- US respiratory virus activity (CDC Respiratory Illnesses)
- ENFLONSIA: novel drug approvals 2025 (FDA)
- RSV-Network (CDC Respiratory Syncytial virus Infection)
- Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV))
- Evaluation of Guillain-Barré Syndrome (GBS) following Respiratory Syncytial Virus (RSV) Vaccination Among Adults 65 Years and Older (FDA)
- Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP)
- Evidence to Recommendations Framework (EtR): RSV Vaccination in Adults Aged 50–59 years (CDC: National Center for Immunization and Respiratory Diseases)
- Waste water scan for 11 pathogens (WastewaterSCan)
- COVID-19 deaths (CDC)
- Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses)
- COVID-19 national and regional trends (CDC)
- COVID-19 variant tracker (CDC)
- SARS-CoV-2 genomes galore (Nextstrain)
- Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV)
- Where to get pemgarda (Pemgarda)
- EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
- Infusion center (Prime Fusions)
- CDC Quarantine guidelines (CDC)
- NIH COVID-19 treatment guidelines (NIH)
- Drug interaction checker (University of Liverpool)
- Paxlovid (Pfizer)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- What to do when sick with a respiratory virus (CDC)
- Managing healthcare staffing shortages (CDC)
- Steroids,dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Daniel Griffin’s evidence based medical practices for long COVID (OFID)
- Long COVID hotline (Columbia : Columbia University Irving Medical Center)
- The answers: Long COVID
- Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study (European Heart Journal)
- Reaching out to US house representative
- Letters read on TWiV 1246
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene Ramsey. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
Content in this podcast should not be construed as medical advice.
The post TWiV 1246: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.
Leave a Reply